Evotec Final H1 2026: Net Loss Widens to €168.6M, Horizon Restructuring Costs Hit €98.9M
EVO sits 16% above its 52-week low of $1.895.
Summary
Evotec SE reported a final H1 2026 net loss of €168.6M, driven by €98.9M in Horizon restructuring costs and a €42.3M impairment, while confirming its lowered full-year guidance.
Key Events · Earnings and Guidance · EVO
-
H1 Net Loss Widens to €168.6M
The net loss for H1 2026 reached €168.6M, up from €75.1M a year earlier, as lower revenues combined with €98.9M in Horizon restructuring costs and a €42.3M impairment on a Hamburg laboratory building.
-
Horizon Restructuring Costs Total €98.9M
The Horizon transformation program incurred €98.9M in reorganization costs, including €48.6M in personnel provisions and €10.6M in restoration obligations, reflecting the scale of the company's cost-cutting measures.
-
Revenue Declines 19.2% to €300.1M
Group revenue fell 19.2% year-over-year to €300.1M, with D&PD revenue down 15.2% and JEB revenue down 29.3%, primarily due to weak sales conversion and the non-repeat of the Sandoz license sale.
-
Full-Year Guidance Confirmed at Lowered Levels
The company confirmed its updated FY2026 outlook of €570-610M in revenue and adjusted EBITDA of -€70M to -€105M, reflecting partnership timing shifts and lower revenue conversion.
Analysis · EVO · Life Sciences
The final half-year report confirms the preliminary figures but adds material new details: a €168.6M net loss, €98.9M in Horizon restructuring costs, a €42.3M impairment on a Hamburg lab building, and the departure of a Supervisory Board member. Liquidity remains solid at €465.6M, but the operating losses and restructuring charges underscore the severity of the revenue decline and the cost of the transformation program.
At the time of this filing, EVO was trading at $2.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $788.1M. The 52-week trading range was $1.90 to $4.27. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.